Lochhamer Str. 11
82152 Planegg/Martinsried, de
+49 (89) 8565-3317
Medigene AG: Veregen® Marketing Authorization Process initiated for eight additional European countries
Decision on marketing authorizations expected in the first half of 2015
Up to now, Veregen® is available in the USA and Canada, in 15 European countries (Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Czech Republic, Slovakia, Hungary, and Poland), and in Taiwan. The drug has obtained market approval in a number of additional countries. Several marketing partnership agreements have been concluded in Europe, Asia, and the Americas.
About Veregen®: Veregen® is indicated for the treatment of external genital and perianal warts (Condylomata acuminata). Veregen® contains a proprietary mixture of catechins and other green tea components extracted from green tea leaves. Sinecatechins 10 % & 15-% Ointment (Veregen®) have been included in the European Guideline for the Management of Anogenital Warts in 2012. In addition, in its current Sexually Transmitted Diseases Treatment Guidelines, the US Centers for Disease Control and Prevention includes Sinecatechins 15% Ointment (Veregen®) as a possible option for treating genital warts.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.